17 completed, 5 recruiting, 2 active not recruiting, 2 enrolling by invitation. 17 Phase 3, 4 Phase 4, 2 Phase 1, 1 Phase 2.
By phase and status
Follow atogepant: new trials by email Literature Review of atogepant trials Research Report on atogepant
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|
Effect of Atogepant on the Vestibulo-Ocular Reflex in Healthy Adults and Adults With Migraine
Atogepant 60 mg, Placebo - Migraine Disorders, Brain, Healthy Adult Participants | Phase 4 | Not yet recruiting | Konrad Peter Weber | 80 | 2027-01-01 | 2026-09-17 |
Comparing Migraine Preventive Therapies vs. Anti-CGRP Therapies for Tinnitus in Patients With Migraine (COMPACT-PM)
Galcanezumab, Erenumab 70 mg, Eptinezumab - Migraine Associated Vertigo, Tinnitus | Phase 4 | Not yet recruiting | Stanford University | 120 | 2026-07-01 | 2026-06-17 |
Comparative Effectiveness of Migraine Preventive Medications: The APT Comparison Study
Atogepant 60 mg, Propranolol 160 mg, Topiramate 100 mg - Migraine | Phase 4 | Recruiting | Mayo Clinic | 1335 | 2025-07-09 | 2026-10-19 |
A Study of Oral Atogepant Tablets to Assess Adverse Events and Change in Disease Activity To Prevent Migraine in Participants Aged 12 to 17 Years
Atogepant, Placebo for Atogepant - Chronic Migraine | Phase 3 | Recruiting | AbbVie | 420 | 2025-02-13 | 2026-10-09 |
Study of Oral Atogepant to Assess Adverse Events and Change in Disease Activity in Adult Participants With Menstrual Migraine
Atogepant, Placebo for Atogepant - Menstrual Migraine (MM) | Phase 3 | Active not recruiting | AbbVie | 468 | 2025-02-10 | 2026-09-04 |
Neurophysiological and Biomolecular Effects of Atogepant in Episodic Migraine
Atogepant 60 mg - Migraine Disorder, Episodic Migraine | | Recruiting | IRCCS National Neurological Institute "C. Mondino" Foundation | 30 | 2024-12-01 | 2025-03-18 |
Post-Marketing Study to Assess the Safety and Effectiveness of Oral Atogepant in Korean Adult Participants for the Prevention of Chronic or Episodic Migraine
Atogepant - Chronic Migraine, Episodic Migraine | | Recruiting | AbbVie | 3000 | 2024-09-24 | 2026-07-22 |
Long-term Atogepant in Real-world Practice
Atogepant 60 mg, Headache diary, Patient-reported outcome measures - Migraine, Headache | | Completed | Fundación de Investigación Biomédica - Hospital Universitario de La Princesa | 513 | 2024-06-01 | 2026-09-23 |
Italian Real-life obServational Study on the effecTiveness, sAfety and Tolerability of Atogepant in Migraine Patients
Atogepant 60 mg - Migraine, Migraine With Aura | | Active not recruiting | University of Florence | 500 | 2024-05-09 | 2026-01-21 |
Atogepant in Real Life in Italy (GIANT)
Atogepant - Migraine, Prophylaxis | | Unknown | IRCCS San Raffaele Roma | 500 | 2024-04-09 | 2024-04-10 |
Migraine Medication Effects on Urinary Symptoms
Ubrogepant, Rimegepant, Atogepant - Overactive Bladder, Bladder Pain Syndrome | | Enrolling by invitation | The Cleveland Clinic | 200 | 2024-04-05 | 2026-10-19 |
Study of Oral Atogepant Tablets to Assess Safety and Efficacy in Adult Participants With Migraine
Atogepant, Placebo for Atogepant - Migraine | Phase 3 | Completed | AbbVie | 2158 | 2024-03-25 | 2026-09-11 |
Comparative Study of Oral Atogepant Versus Oral Topiramate to Assess Adverse Events in Adult Participants With Migraine
Atogepant, Placebo for Atogepant, Topiramate - Migraine | Phase 3 | Completed | AbbVie | 545 | 2023-10-07 | 2026-07-02 |
Study of Oral Atogepant Tablets to Assess Change in Disease Activity in Adult Japanese Participants With Episodic Migraine
Atogepant, Placebo for Atogepant - Migraine | Phase 3 | Completed | AbbVie | 524 | 2023-07-12 | 2026-06-11 |
Study to Assess Adverse Events and Compare How Oral Ubrogepant and Oral Atogepant Moves Through the Body of Healthy Female Adult Volunteers
Atogepant, Ubrogepant - Healthy Volunteers | Phase 1 | Completed | AbbVie | 24 | 2023-07-11 | 2024-03-12 |
Long-term Extension Study to Assess Adverse Events of Oral Atogepant Tablets in Pediatric Participants (6 to 17 Years of Age) With Migraine
Atogepant - Migraine Prophylaxis | Phase 3 | Enrolling by invitation | AbbVie | 650 | 2023-06-05 | 2025-08-11 |
A Study to Assess the Adverse Events and Change in Disease Activity of Oral Atogepant Tablets in Pediatric Participants (6-17 Years of Age) With Episodic Migraine
Atogepant, Placebo-Matching Atogepant - Episodic Migraine | Phase 3 | Recruiting | AbbVie | 450 | 2023-05-01 | 2026-10-06 |
Study of Oral Atogepant When Added to OnabotulinumtoxinA (BOTOX) to Assess Adverse Events and Change in Disease Activity in Adult Participants With Chronic Migraine
Atogepant - Chronic Migraine | Phase 3 | Completed | AbbVie | 75 | 2022-03-22 | 2026-06-16 |
Study to Assess Adverse Events When Ubrogepant Tablets in Combination With Atogepant Tablets Are Used to Treat Adult Participants With Migraine
Atogepant, Ubrogepant - Episodic Migraine | Phase 4 | Completed | AbbVie | 263 | 2022-03-07 | 2024-10-08 |
Study to Assess Adverse Events (AEs) When Oral Atogepant Tablet is Given to Adult Chinese Participants Who Completed Study 3101-303-002 to Prevent Chronic Migraine
Atogepant - Chronic Migraine | Phase 3 | Completed | Allergan | 3 | 2021-08-02 | 2023-05-24 |
Showing 20 of 29. Sign in to see all of them.
Conditions studied
Migraine Disorders (19) · Epilepsy (2) · Headache (2) · Migraine with Aura (2) · Cystitis, Interstitial (1) · Headache Disorders, Secondary (1) · Migraine without Aura (1) · Pain (1) · Prescription Drug Overuse (1) · Tinnitus (1) · Urinary Bladder, Overactive (1)
Sponsors
AbbVie (14) · Allergan (7) · Fundación de Investigación Biomédica - Hospital Universitario de La Princesa (1) · IRCCS National Neurological Institute "C. Mondino" Foundation (1) · IRCCS San Raffaele Roma (1) · Konrad Peter Weber (1) · Mayo Clinic (1) · Stanford University (1) · The Cleveland Clinic (1) · University of Florence (1)
Countries
United States (16) · Italy (11) · Poland (9) · United Kingdom (9) · Hungary (8) · Japan (8) · Spain (8) · Canada (7) · Czechia (6) · Denmark (6) · France (6) · Germany (6) · Netherlands (5) · South Korea (5) · Sweden (5)
Top investigators
Joel Trugman, MD (4) · Ana Beatriz Gago Veiga (1) · Howard B Goldman, MD (1) · Konrad P Weber, Prof. (1) · Kristen K. Steenerson (1) · Matthew Fitzgerald (1) · Todd J Schwedt, M.D. (1)
Results publications
PMID 33142014, PMID 39648629, PMID 33942560, PMID 38462625, PMID 39982105, PMID 39648617, PMID 39715475, PMID 32822633, PMID 34407343, PMID 38773375, PMID 41235617, PMID 34521260, PMID 35675076, PMID 36396451, PMID 37516125, PMID 37638400, PMID 38364831, PMID 38924724, PMID 39569702, PMID 40267275, PMID 40391560, PMID 40455369, PMID 40471213, PMID 40831083, PMID 41002192, PMID 41222899, PMID 41620660, PMID 41814051, PMID 41878762, PMID 41920093, PMID 41944477, PMID 42265882, PMID 42360082, PMID 42492556
NIH funding
2018 (1), 2019 (1), 2023 (1)